RLAYRelay Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Relay Therapeutics, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLAYEsta | $4.2B#6 | — | 4.7x#1 | 270.9x#5 | 53.4%#2 | 18.1%#4 | -1971.6%#5 | -31.1%#3 | — | — | 368.1%#2 | — |
| MRNA | $57.4B#1 | — | 8.5x#2 | 29.5x#2 | -39.9%#5 | 20.8%#3 | -158.1%#3 | -41.7%#4 | -54.6%#2 | — | — | — |
| TWST | $8.6B#4 | — | 19.4x#4 | 23.0x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#2 | -41.4%#1 | — | 435.7%#1 | — |
| RVMD | $43.9B#2 | — | 16.9x#3 | — | — | -88.5%#6 | — | -43.4%#5 | — | — | — | — |
| RYTM | $6.7B#5 | — | 64.7x#5 | 35.1x#3 | 45.8%#3 | 24.6%#2 | -101.2%#2 | -0.2%#1 | -133.8%#3 | — | — | — |
| CYTK | $9.6B#3 | — | — | 109.5x#4 | 376.6%#1 | -33.2%#5 | -695.4%#4 | — | — | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice